Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553
GlobeNewswire - Thu Jun 25, 12:21AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 1/2a study with an oral formulation of its anti-cancer drug candidate BAL101553. BAL101553 is a microtubule-destabilizing small molecule, acting as tumor checkpoint controller (TCC) as it promotes tumor cell death through activation of an important checkpoint in cell proliferation.
Gastroesophageal (GE) Junction Carcinomas Pipeline Review, H1 2015 - 14 Companies & 17 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/27fwrv/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Basilea Pharmaceutica AG - Bristol-Myers Squibb Company - Celltrion, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Merck & Co., Inc. - Merck KGaA - Merrimack Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Taiho Pharmaceutical Co., Ltd. Drug Profiles - (tegafur gimeracil oteracil) - avelumab - BAL-101553 - cabozantinib s-malate - DKN-01 - gefitinib - GS-5745 - ipilimumab - MK-2206 - MM-111 - nimotuzumab - nivolumab - pertuzumab - SNX-5422 - trastuzumab biosimilar - trebananib - varlitinib For more information visit http://www.researchandmarkets.com/research/27...esophageal
MACK: 12.08 (+0.43), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)
Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor
GlobeNewswire - Mon May 04, 12:54PM CDT
Basilea Pharmaceutica Ltd. (SIX:BSLN) reported today the start of a clinical phase 1 study with the orally administered investigational drug BAL3833/CCT3833 in patients with advanced solid tumors. BAL3833/CCT3833 is the lead compound of a series of small molecule panRAF inhibitors recently in-licensed by Basilea.
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
GlobeNewswire - Wed Apr 29, 11:12AM CDT
Basel, Switzerland, April 29, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2014, shareholders approved all agenda items proposed by the Board of Directors. At the meeting, 45.3 percent of Basilea's share capital was represented.
Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID
GlobeNewswire - Fri Apr 24, 12:18AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that a broad range of scientific data will be presented on the antifungal isavuconazole and the antibiotic ceftobiprole at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Copenhagen, Denmark, from 25 - 28 April 2015.
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 12.08 (+0.43), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)
Basilea in-licenses targeted cancer therapy
GlobeNewswire - Wed Apr 01, 12:18AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has entered into a license agreement for novel panRAF kinase inhibitors with a consortium of organizations including The Institute of Cancer Research, London, Cancer Research Technology, the Wellcome Trust and The University of Manchester.
Basilea Pharmaceutica's (BPMUF) CEO Ronald Scott on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 2:03PM CST
Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera(R) in Europe
Thomson Reuters ONE - Tue Feb 17, 12:15AM CST
Basilea Pharmaceutica AG / Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera(R) in Europe . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis
GlobeNewswire - Thu Jan 22, 2:12PM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted unanimously to recommend approval of the investigational once-daily intravenous and oral antifungal isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, for the treatment of invasive aspergillosis, and eight to two with one abstention to recommend approval for the treatment of invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients. Basilea's partner Astellas presented the data to the FDA and, if approved, intends to market the drug as Cresemba in the United States.
Aspergillosis - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/tnt27n/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Aspergillosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Eisai Co., Ltd. - F2G Ltd - MABLife S.A.S - Merck & Co., Inc. - Novabiotics Ltd - Sealife PHARMA GMBH - Sigma-Tau S.p.A. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/tn...ergillosis
MRK: 57.95 (+0.57)
Swissmedic approves Basilea's antibiotic Zevtera(r) (ceftobiprole medocaril) for the treatment of pneumonia
GlobeNewswire - Mon Dec 22, 12:18AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the Swiss regulatory authority Swissmedic has approved the antibiotic Zevtera (ceftobiprole medocaril) for the treatment in adults of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). The license will be issued by Swissmedic following formal publication of the Product Information. Ceftobiprole for the treatment of pneumonia has already been approved in twelve other European countries.
Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/24xkp9/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Actavis plc - Cempra, Inc. - Pfizer Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC - Nabriva Therapeutics AG - Cubist Pharmaceuticals, Inc. - Boehringer Ingelheim Auslandsbeteiligungs GmbH - Bayer AG - Basilea Pharmaceutica AG Clinical Trial Overview of Top Institutes / Government - Yokohama Rosai Hospital - Nagasaki Evaluation Organization for Clinical Interventions - Central Japan Lung Study Group - Albany Medical Center For more information visit http://www.researchandmarkets.com/research/24...tyacquired
CBSTZ: 0.06 (unch), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), CEMP: 36.27 (+2.26)